致力于提高微生物群对癌症免疫治疗的预测价值。
Towards enhancing the predictive value of the microbiota for cancer immunotherapy.
发表日期：2024 Jul 31
作者：
Amiran K Dzutsev, Romina S Goldszmid
来源：
Trends in Cancer
摘要：
肠道微生物群已成为免疫检查点抑制剂（ICI）反应的潜在决定因素，但将其用作生物标志物仍然具有挑战性。 Derosa 等人最近在《细胞》杂志上进行的一项研究。描述了一种基于肠道微生物群组成的两层模型，用于区分有反应的癌症患者和无反应的癌症患者，提供了可在临床中利用的新想法。由爱思唯尔公司出版。
The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in Cell by Derosa et al. describes a two-tier model based on gut microbiota composition to discriminate responder from non-responder patients with cancer, offering new ideas that could be leveraged in the clinic.Published by Elsevier Inc.